ESTRO 2022 - Abstract Book

S1444

Abstract book

ESTRO 2022

proton treatment planning system. According to the dosimetric validations, dose distributions with and without range shifter were comparable between dose calculations and measurements within the acceptable clinical criteria (within 3%).

Conclusion The first proton therapy center in Thailand was successfully commissioned. The acceptable verification results and the dosimetric validations ensured that the proton therapy system is ready for clinical use.

PO-1648 Cell kill based treatment planning for polymetastatic patients with high tumor burden

N. Torelli 1 , Y. Wang 1 , S. Burgermeister 1 , H.S. Gabry ś 1 , I. Madani 1 , M. Guckenberger 1 , J. Unkelbach 1

1 University Hospital Zurich and University of Zurich, Department of Radiation Oncology, Zurich, Switzerland

Purpose or Objective In patients with oligometastatic diseases, the early integration of local metastases directed treatment into a multimodality treatment strategy has shown improved clinical outcomes and is nowadays considered a standard treatment option. Recently, it has been proposed to transfer the principles of oligometastatic disease into treatment of polymetastatic cancer patients. Although local ablation of all visible metastases may not be feasible in this situation due to dosimetric constraints,